At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 8 enrolled
Drug / intervention
GM-CSF +1 moredrug
Likely dose
GM-CSF 125 µgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Neoadjuvant GM-CSF Treatment and Modulation of Immune Cell Profile of the SLN in Melanoma
In Brief
A Phase 4 clinical trial evaluating GM-CSF and Standard of Care for Melanoma. Completed, enrolled 8 participants across 1 site.
Detailed Summary
Randomized trial to determine if neo-adjuvant subcutaneous GM-CSF restores the host regional lymph node immunity
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMelanoma
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartMay 2015
First PostedMay 2015
Primary CompletionNov 2016
TodayJul 2026
First PostedMay 22, 2015
Enrollment StartMay 1, 2015
Primary CompletionNov 4, 2016
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 11.1 years ago
Interventions
GM-CSFdrug
14 days in a dose of 125 µg/m\^2
Standard of Careother
No neo-adjuvant therapy prior to surgical intervention